You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetipranolol
Accession NumberDB01214  (APRD00668)
TypeSmall Molecule
GroupsApproved
DescriptionA beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]
Structure
Thumb
Synonyms
(+-)-Metipranolol
Acetic acid 4-(2-hydroxy-3-isopropylamino-propoxy)-2,3,6-trimethyl-phenyl ester
Metipranolol
Metipranololum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metipranololsolution/ drops3 mg/mLophthalmicFalcon Pharmaceuticals, Ltd.2001-08-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetanolNot Available
DisoratNot Available
OptiPranololNot Available
TrimepranolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Metipranolol hydrochloride
Thumb
  • InChI Key: BLWNYSZZZWQCKO-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.170686096
  • Average Mass: 345.862
DBSALT000806
Categories
UNIIX39AL81KEB
CAS number22664-55-7
WeightAverage: 309.4006
Monoisotopic: 309.194008357
Chemical FormulaC17H27NO4
InChI KeyInChIKey=BQIPXWYNLPYNHW-UHFFFAOYSA-N
InChI
InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3
IUPAC Name
4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-2,3,6-trimethylphenyl acetate
SMILES
CC(C)NCC(O)COC1=C(C)C(C)=C(OC(C)=O)C(C)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol esters
Direct ParentPhenol esters
Alternative Parents
Substituents
  • Phenol ester
  • Phenol ether
  • Alkyl aryl ether
  • Acetate salt
  • Secondary alcohol
  • Carboxylic acid ester
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationIndicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
PharmacodynamicsMetipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.
Mechanism of actionAlthough it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Metipranolol Action PathwayDrug actionSMP00667
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8638
Blood Brain Barrier-0.9906
Caco-2 permeable-0.5988
P-glycoprotein substrateSubstrate0.6335
P-glycoprotein inhibitor INon-inhibitor0.7599
P-glycoprotein inhibitor IINon-inhibitor0.8296
Renal organic cation transporterNon-inhibitor0.9097
CYP450 2C9 substrateNon-substrate0.8014
CYP450 2D6 substrateSubstrate0.5086
CYP450 3A4 substrateNon-substrate0.6564
CYP450 1A2 substrateNon-inhibitor0.6333
CYP450 2C9 inhibitorNon-inhibitor0.8721
CYP450 2D6 inhibitorNon-inhibitor0.7104
CYP450 2C19 inhibitorNon-inhibitor0.9547
CYP450 3A4 inhibitorNon-inhibitor0.8282
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.9219
CarcinogenicityNon-carcinogens0.9205
BiodegradationNot ready biodegradable0.7546
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.7745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic3 mg/mL
Prices
Unit descriptionCostUnit
Optipranolol 0.3% Solution 10ml Bottle42.99USD bottle
Optipranolol 0.3% Solution 5ml Bottle25.99USD bottle
Optipranolol 0.3% eye drops5.08USD ml
Metipranolol 0.3% eye drops3.55USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105-107 °CPhysProp
water solubility589 mg/LNot Available
logP2.66MANNHOLD,R ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.13ALOGPS
logP2.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.79 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity86.63 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07BA68S01ED54S01ED04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metipranolol.
AcebutololAcebutolol may increase the hypotensive activities of Metipranolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Metipranolol.
AcepromazineAcepromazine may increase the hypotensive activities of Metipranolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Metipranolol.
AcetohexamideMetipranolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Acetylcholine.
AcetyldigitoxinMetipranolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Metipranolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Metipranolol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Metipranolol.
AlimemazineAlimemazine may increase the hypotensive activities of Metipranolol.
AliskirenMetipranolol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Metipranolol.
AmbrisentanMetipranolol may increase the hypotensive activities of Ambrisentan.
AmifostineMetipranolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Metipranolol.
AmiodaroneAmiodarone may increase the bradycardic activities of Metipranolol.
AmlodipineAmlodipine may increase the hypotensive activities of Metipranolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Metipranolol.
AmodiaquineThe metabolism of Metipranolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Metipranolol can be increased when it is combined with Amoxapine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Metipranolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Metipranolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Metipranolol.
ApremilastApremilast may decrease the antihypertensive activities of Metipranolol.
ArecolineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Arecoline.
AripiprazoleAripiprazole may increase the hypotensive activities of Metipranolol.
AtenololAtenolol may increase the hypotensive activities of Metipranolol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Metipranolol.
AzelastineAzelastine may decrease the antihypertensive activities of Metipranolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metipranolol is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the antihypertensive activities of Metipranolol.
BarbitalBarbital may increase the hypotensive activities of Metipranolol.
BenazeprilBenazepril may increase the hypotensive activities of Metipranolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Metipranolol.
BenmoxinBenmoxin may increase the hypotensive activities of Metipranolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Metipranolol.
BepridilMetipranolol may increase the hypotensive activities of Bepridil.
BeractantMetipranolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Metipranolol.
BethanecholThe risk or severity of adverse effects can be increased when Metipranolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Metipranolol.
BimatoprostBimatoprost may increase the hypotensive activities of Metipranolol.
BisoprololBisoprolol may increase the hypotensive activities of Metipranolol.
BosentanBosentan may increase the hypotensive activities of Metipranolol.
BretyliumBretylium may increase the bradycardic activities of Metipranolol.
BretyliumMetipranolol may increase the hypotensive activities of Bretylium.
BrimonidineMetipranolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Metipranolol.
BromfenacBromfenac may decrease the antihypertensive activities of Metipranolol.
BromocriptineMetipranolol may increase the vasoconstricting activities of Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Metipranolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Metipranolol.
BupranololMetipranolol may increase the hypotensive activities of Bupranolol.
CabergolineMetipranolol may increase the vasoconstricting activities of Cabergoline.
CalfactantMetipranolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Metipranolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Metipranolol.
CaptoprilCaptopril may increase the hypotensive activities of Metipranolol.
CarbacholThe risk or severity of adverse effects can be increased when Metipranolol is combined with Carbachol.
CaroxazoneCaroxazone may increase the hypotensive activities of Metipranolol.
CarprofenCarprofen may decrease the antihypertensive activities of Metipranolol.
CarteololCarteolol may increase the hypotensive activities of Metipranolol.
CarvedilolCarvedilol may increase the hypotensive activities of Metipranolol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Metipranolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Metipranolol.
CeliprololMetipranolol may increase the hypotensive activities of Celiprolol.
CeritinibMetipranolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Metipranolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Metipranolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Metipranolol.
ChlorpropamideMetipranolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Metipranolol.
CilazaprilMetipranolol may increase the hypotensive activities of Cilazapril.
ClevidipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.
ClomipramineThe serum concentration of Metipranolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Metipranolol.
ClonixinClonixin may decrease the antihypertensive activities of Metipranolol.
CrizotinibMetipranolol may increase the bradycardic activities of Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Metipranolol.
CyclothiazideCyclothiazide may increase the hypotensive activities of Metipranolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Metipranolol.
DapagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Metipranolol can be increased when it is combined with Dapoxetine.
DebrisoquinMetipranolol may increase the hypotensive activities of Debrisoquin.
DeserpidineMetipranolol may increase the hypotensive activities of Deserpidine.
DeslanosideMetipranolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metipranolol.
DiazoxideDiazoxide may increase the hypotensive activities of Metipranolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Metipranolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Metipranolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Metipranolol.
DigitoxinMetipranolol may increase the bradycardic activities of Digitoxin.
DigoxinMetipranolol may increase the bradycardic activities of Digoxin.
DihydroergotamineMetipranolol may increase the vasoconstricting activities of Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Metipranolol.
DinutuximabThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dinutuximab.
DipyridamoleDipyridamole may increase the bradycardic activities of Metipranolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Metipranolol.
DonepezilDonepezil may increase the bradycardic activities of Metipranolol.
DorzolamideDorzolamide may increase the hypotensive activities of Metipranolol.
DoxazosinDoxazosin may increase the hypotensive activities of Metipranolol.
DronedaroneMetipranolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Metipranolol.
DuloxetineMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineMetipranolol may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Metipranolol.
EnalaprilatMetipranolol may increase the hypotensive activities of Enalaprilat.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Metipranolol is combined with EPIBATIDINE.
EpirizoleEpirizole may decrease the antihypertensive activities of Metipranolol.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Metipranolol.
EpoprostenolMetipranolol may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Metipranolol.
Ergoloid mesylateMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineMetipranolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineMetipranolol may increase the vasoconstricting activities of Ergotamine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metipranolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Metipranolol.
EtodolacEtodolac may decrease the antihypertensive activities of Metipranolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Metipranolol.
EtoperidoneThe serum concentration of Metipranolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Metipranolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Metipranolol.
exisulindexisulind may decrease the antihypertensive activities of Metipranolol.
FelodipineFelodipine may increase the hypotensive activities of Metipranolol.
FenbufenFenbufen may decrease the antihypertensive activities of Metipranolol.
FenfluramineThe serum concentration of Metipranolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Metipranolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Metipranolol.
FingolimodMetipranolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metipranolol.
FlunixinFlunixin may decrease the antihypertensive activities of Metipranolol.
FluoxetineThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Metipranolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Metipranolol.
FosinoprilFosinopril may increase the hypotensive activities of Metipranolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Metipranolol.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Metipranolol.
GalantamineGalantamine may increase the bradycardic activities of Metipranolol.
GlibornurideMetipranolol may increase the hypoglycemic activities of Glibornuride.
GliclazideMetipranolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideMetipranolol may increase the hypoglycemic activities of Glimepiride.
GlipizideMetipranolol may increase the hypoglycemic activities of Glipizide.
GliquidoneMetipranolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideMetipranolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideMetipranolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Metipranolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Metipranolol.
GuanadrelGuanadrel may increase the hypotensive activities of Metipranolol.
GuanethidineGuanethidine may increase the hypotensive activities of Metipranolol.
GuanfacineGuanfacine may increase the hypotensive activities of Metipranolol.
HexamethoniumMetipranolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Metipranolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Metipranolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Metipranolol.
HydralazineMetipranolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Metipranolol.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Metipranolol.
HydroxychloroquineThe metabolism of Metipranolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Metipranolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Metipranolol.
IcatibantIcatibant may decrease the antihypertensive activities of Metipranolol.
IloprostIloprost may increase the hypotensive activities of Metipranolol.
IndalpineThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Metipranolol.
IndenololMetipranolol may increase the hypotensive activities of Indenolol.
IndomethacinIndomethacin may decrease the antihypertensive activities of Metipranolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Metipranolol.
IndoraminMetipranolol may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Metipranolol.
IproniazidIproniazid may increase the hypotensive activities of Metipranolol.
IrbesartanIrbesartan may increase the hypotensive activities of Metipranolol.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metipranolol.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Metipranolol.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Metipranolol.
IsoxicamIsoxicam may decrease the antihypertensive activities of Metipranolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Metipranolol.
IvabradineMetipranolol may increase the bradycardic activities of Ivabradine.
KebuzoneKebuzone may decrease the antihypertensive activities of Metipranolol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Metipranolol.
KetorolacKetorolac may decrease the antihypertensive activities of Metipranolol.
LabetalolLabetalol may increase the hypotensive activities of Metipranolol.
LacidipineMetipranolol may increase the hypotensive activities of Lacidipine.
LacosamideMetipranolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideMetipranolol may increase the bradycardic activities of Lanreotide.
LatanoprostLatanoprost may increase the hypotensive activities of Metipranolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Metipranolol.
LercanidipineLercanidipine may increase the hypotensive activities of Metipranolol.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Metipranolol.
LevodopaMetipranolol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Metipranolol.
LisinoprilLisinopril may increase the hypotensive activities of Metipranolol.
LobelineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Lobeline.
LofexidineMetipranolol may increase the hypotensive activities of Lofexidine.
LornoxicamLornoxicam may decrease the antihypertensive activities of Metipranolol.
LosartanLosartan may increase the hypotensive activities of Metipranolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Metipranolol.
Lu AA21004The serum concentration of Metipranolol can be increased when it is combined with Lu AA21004.
LucinactantMetipranolol may increase the bradycardic activities of Lucinactant.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Metipranolol.
MacitentanMetipranolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.
ManidipineMetipranolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Metipranolol.
MebanazineMebanazine may increase the hypotensive activities of Metipranolol.
MecamylamineMecamylamine may increase the hypotensive activities of Metipranolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Metipranolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Metipranolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.
MesalazineMesalazine may decrease the antihypertensive activities of Metipranolol.
MesoridazineMesoridazine may increase the hypotensive activities of Metipranolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Metipranolol.
MethacholineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Methacholine.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Metipranolol.
MethohexitalMethohexital may increase the hypotensive activities of Metipranolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Metipranolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metipranolol.
MethyldopaMethyldopa may increase the hypotensive activities of Metipranolol.
Methylene blueMethylene blue may increase the hypotensive activities of Metipranolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metipranolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Metipranolol.
MetoprololMetoprolol may increase the hypotensive activities of Metipranolol.
MibefradilMetipranolol may increase the hypotensive activities of Mibefradil.
MidodrineMetipranolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Metipranolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the hypotensive activities of Metipranolol.
MinoxidilMinoxidil may increase the hypotensive activities of Metipranolol.
MoclobemideMoclobemide may increase the hypotensive activities of Metipranolol.
MoexiprilMoexipril may increase the hypotensive activities of Metipranolol.
MolsidomineMolsidomine may increase the hypotensive activities of Metipranolol.
MoricizineMoricizine may increase the hypotensive activities of Metipranolol.
MoxonidineMetipranolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Metipranolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Metipranolol.
NadololNadolol may increase the hypotensive activities of Metipranolol.
NaftifineNaftifine may decrease the antihypertensive activities of Metipranolol.
NaproxenNaproxen may decrease the antihypertensive activities of Metipranolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Metipranolol.
NebivololMetipranolol may increase the hypotensive activities of Nebivolol.
NepafenacNepafenac may decrease the antihypertensive activities of Metipranolol.
NesiritideThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Metipranolol.
NicardipineNicardipine may increase the hypotensive activities of Metipranolol.
NicorandilNicorandil may increase the hypotensive activities of Metipranolol.
NicotineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Metipranolol.
NifedipineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Metipranolol.
NiguldipineMetipranolol may increase the hypotensive activities of Niguldipine.
NilvadipineMetipranolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Metipranolol.
NimodipineNimodipine may increase the hypotensive activities of Metipranolol.
NisoldipineNisoldipine may increase the hypotensive activities of Metipranolol.
NitrendipineNitrendipine may increase the hypotensive activities of Metipranolol.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Metipranolol.
NitroprussideNitroprusside may increase the hypotensive activities of Metipranolol.
ObinutuzumabMetipranolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Metipranolol.
OctreotideOctreotide may increase the bradycardic activities of Metipranolol.
OlanzapineThe serum concentration of Metipranolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Metipranolol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Metipranolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Metipranolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Metipranolol.
OrgoteinOrgotein may decrease the antihypertensive activities of Metipranolol.
OuabainMetipranolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Metipranolol.
OxprenololMetipranolol may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Metipranolol.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Metipranolol.
PargylineMetipranolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.
PasireotideMetipranolol may increase the bradycardic activities of Pasireotide.
PenbutololMetipranolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Metipranolol.
PentoliniumPentolinium may increase the hypotensive activities of Metipranolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metipranolol.
PerindoprilPerindopril may increase the hypotensive activities of Metipranolol.
PerphenazinePerphenazine may increase the hypotensive activities of Metipranolol.
PhenelzinePhenelzine may increase the hypotensive activities of Metipranolol.
PheniprazinePheniprazine may increase the hypotensive activities of Metipranolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Metipranolol.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Metipranolol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metipranolol.
PhentolaminePhentolamine may increase the hypotensive activities of Metipranolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Metipranolol.
PilocarpineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Metipranolol.
PinacidilMetipranolol may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Metipranolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Metipranolol.
PirlindolePirlindole may increase the hypotensive activities of Metipranolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Metipranolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Metipranolol.
PolythiazideMetipranolol may increase the hypotensive activities of Polythiazide.
Poractant alfaMetipranolol may increase the bradycardic activities of Poractant alfa.
PrazosinPrazosin may increase the hypotensive activities of Metipranolol.
PrimaquineThe metabolism of Metipranolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Metipranolol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Metipranolol.
PromazinePromazine may increase the hypotensive activities of Metipranolol.
PromethazinePromethazine may increase the hypotensive activities of Metipranolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Metipranolol.
PropafenoneThe serum concentration of Metipranolol can be increased when it is combined with Propafenone.
PropafenoneMetipranolol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Metipranolol.
PTC299PTC299 may decrease the antihypertensive activities of Metipranolol.
QuetiapineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Metipranolol.
QuinineQuinine may increase the hypotensive activities of Metipranolol.
RamiprilRamipril may increase the hypotensive activities of Metipranolol.
RasagilineRasagiline may increase the hypotensive activities of Metipranolol.
RegorafenibRegorafenib may increase the bradycardic activities of Metipranolol.
RemikirenRemikiren may increase the hypotensive activities of Metipranolol.
RescinnamineMetipranolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Metipranolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Metipranolol.
RiociguatMetipranolol may increase the hypotensive activities of Riociguat.
RisperidoneMetipranolol may increase the hypotensive activities of Risperidone.
RituximabMetipranolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Metipranolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Metipranolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Metipranolol.
SafrazineSafrazine may increase the hypotensive activities of Metipranolol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Metipranolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Metipranolol.
SalsalateSalsalate may decrease the antihypertensive activities of Metipranolol.
SaprisartanMetipranolol may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Metipranolol.
SelegilineSelegiline may increase the hypotensive activities of Metipranolol.
SelexipagMetipranolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Metipranolol.
SertralineThe serum concentration of Metipranolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Metipranolol.
SitaxentanMetipranolol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metipranolol.
SpiraprilMetipranolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metipranolol.
SRT501SRT501 may decrease the antihypertensive activities of Metipranolol.
SufentanilSufentanil may increase the bradycardic activities of Metipranolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Metipranolol.
SulindacSulindac may decrease the antihypertensive activities of Metipranolol.
SuprofenSuprofen may decrease the antihypertensive activities of Metipranolol.
TadalafilTadalafil may increase the antihypertensive activities of Metipranolol.
TelmisartanTelmisartan may increase the hypotensive activities of Metipranolol.
TemocaprilMetipranolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Metipranolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Metipranolol.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Metipranolol.
TerlipressinMetipranolol may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Metipranolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Metipranolol.
ThiopentalThiopental may increase the hypotensive activities of Metipranolol.
ThioridazineThioridazine may increase the hypotensive activities of Metipranolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Metipranolol.
TiboloneMetipranolol may increase the hypotensive activities of Tibolone.
TicrynafenMetipranolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Metipranolol.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Metipranolol.
TofacitinibTofacitinib may increase the bradycardic activities of Metipranolol.
TolazamideMetipranolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Metipranolol.
TolbutamideMetipranolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Metipranolol.
TolmetinTolmetin may decrease the antihypertensive activities of Metipranolol.
ToloxatoneToloxatone may increase the hypotensive activities of Metipranolol.
TorasemideTorasemide may increase the hypotensive activities of Metipranolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Metipranolol.
TranilastTranilast may decrease the antihypertensive activities of Metipranolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metipranolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Metipranolol.
TravoprostTravoprost may increase the hypotensive activities of Metipranolol.
TrazodoneThe serum concentration of Metipranolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Metipranolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Metipranolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Metipranolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Metipranolol.
TrimazosinMetipranolol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Metipranolol.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Metipranolol.
UdenafilUdenafil may increase the antihypertensive activities of Metipranolol.
UnoprostoneMetipranolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Metipranolol.
ValsartanValsartan may increase the hypotensive activities of Metipranolol.
VardenafilVardenafil may increase the antihypertensive activities of Metipranolol.
VareniclineThe risk or severity of adverse effects can be increased when Metipranolol is combined with Varenicline.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.
VilazodoneThe serum concentration of Metipranolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Metipranolol can be increased when it is combined with Vortioxetine.
XylometazolineMetipranolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Metipranolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Metipranolol.
ZileutonZileuton may decrease the antihypertensive activities of Metipranolol.
ZimelidineThe serum concentration of Metipranolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Metipranolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037 ]
  4. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722 ]
  5. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Drimal J, Knezl V, Magna D, Strizova K: External transport of beta-adrenergic binding sites in ischemic myocardium. Gen Physiol Biophys. 1987 Dec;6(6):583-91. [PubMed:2895037 ]
  4. Noack E: [Antiglaucomatous effectiveness of beta receptor blockers with special reference to metipranolol]. Klin Monbl Augenheilkd. 1986 Jul;189(1):1-3. [PubMed:2876128 ]
  5. Arai K, Wood JP, Osborne NN: Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms. Brain Res. 2003 Sep 26;985(2):176-86. [PubMed:12967722 ]
  6. Bilcikova L, Bauer V, Kolena J: The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea. Gen Physiol Biophys. 1987 Feb;6(1):87-101. [PubMed:2885244 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23